Fuhong Hanlin (02696): The international multicenter phase 3 clinical trial application of HLX22 in combination with XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastroesophageal junction and gastric cancer has been approved in Germany.

Zhtng cijng APP xn, f hng hn ln (02696) gngb, jnr, HLX22 (chngz rn yun hu kng HER2 dn k hu t zhng y) (HLX22) linh q tu zh dn kng h hu lio (XELOX) dub q tu zh dn kng h hu (XELOX) linh hu b linh p b l zh dn kng yxin zhlio HER2 yngxng jb wnq hu zhunyng x gun ji b h wi cnc de guj du zhngxn 3 q lnchun shyn shnqng y dgu hub. Gngs n y tiojin j bi hu y dgu j qt u lin guji kizhn lnchun shyn.